Case Report
Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
Table 1
Laboratory results at the start of SOF/RBV combination therapy (2015/9).
| CBC | | | WBC | 3.4 | ×103/μL | RBC | 3.3 | ×106/μL | Hb | 10.4 | g/dL | Hct | 29.9 | % | MCV | 90.6 | fL | Plt | 159 | ×103/μL | Reticulocyte | 1.37 | % | Coagulation | | | PT | 81 | % |
| Tumor marker | | | AFP | 3.6 | ng/mL | PIVKA-II | 18 | mAU/mL |
| HCV viral marker | | | HCV RNA | 6.14 | | HCV genotype | 2b | | Biochemistry | | | TP | 7.2 | g/dL | Alb | 4.2 | g/dL | Ferritin | 98 | ng/ml | T-Bil | 0.9 | mg/dL | D-Bil | 0.1 | U/L | ID-Bil | 0.8 | U/L | AST | 37 | U/L | ALT | 26 | U/L | LDH | 227 | U/L | ALP | 134 | U/L | γ-GTP | 13 | U/L | BUN | 10.9 | mg/dL | Cr | 0.63 | mg/dL | eGFR | 69.1 | ml/min/1.73 m2 | T-chol | 199 | mg/dL |
| IL-28B genotype | TT | | (rs8099917) | | | ITPA | C/A | | (rs7270101) | | |
| FIB-4 index | 3.38 | | Fibro scan | 4.3 | Kpa (F0 level) | CAP | 206 | dB/m (S0 level) |
| Height | 148 | cm | Weight | 49.8 | kg |
|
|
Transient elastography (Fibroscan®). CAP: controlled attenuation parameter.
|